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Zika virus (ZIKV) causes severe neurologic complica-
tions and fetal aberrations. Vaccine development is
hindered by potential safety concerns due to anti-
body cross-reactivity with dengue virus and the pos-
sibility of disease enhancement. In contrast, passive
administration of anti-ZIKV antibodies engineered to
prevent enhancement may be safe and effective.
Here, we report on human monoclonal antibody
Z021, a potent neutralizer that recognizes an epitope
on the lateral ridge of the envelope domain III (EDIII)
of ZIKV and is protective against ZIKV in mice.
When administered to macaques undergoing a
high-dose ZIKV challenge, a single anti-EDIII anti-
body selected for resistant variants. Co-administra-
tion of two antibodies, Z004 and Z021, which target
distinct sites on EDIII, was associated with a delay
and a 3- to 4-log decrease in peak viremia.
Moreover, the combination of these antibodies
engineered to avoid enhancement prevented viral
escape due to mutation in macaques, a natural
host for ZIKV.
INTRODUCTION
Zika virus (ZIKV) is a member of the Flavivirus genus, which in-
cludes four serotypes of dengue virus (DENV1–4),West Nile virus
(WNV), yellow fever virus (YFV), and other vector-borne virusesCell Rep
This is an open access article under the CC BY-Nthat cause human morbidity and mortality (Weaver and Reisen,
2010). ZIKV causes mild symptoms consisting of fever, head-
ache, rash, conjunctivitis, and arthralgia in an estimated 20%
of infected individuals. In addition, infection is occasionally asso-
ciated with severe neurologic problems that require hospitaliza-
tion, such as meningoencephalitis or the immune-mediated
Guillain-Barre´ syndrome (Miner and Diamond, 2017; Mun˜oz
et al., 2016). The most severe consequences of infection are
manifest in fetuses, which can develop devastating develop-
mental aberrations, including microcephaly, collectively referred
to as congenital Zika syndrome (Brasil et al., 2016; Del Campo
et al., 2017). Infection ofmacaques, a natural host of ZIKV, during
pregnancy frequently leads to fetal demise (Dudley et al., 2018),
and in some non-human primate models, prenatal and early
postnatal infection is associated with fetal and infant neuropa-
thology and persistent functional and behavioral abnormalities
(Coffey et al., 2018; Mavigner et al., 2018).
There are no approved treatments for ZIKV. Vaccines for
ZIKV are under development, but the path to approval may be
exceedingly difficult because of antibody cross-reactivity with
other flaviviruses and the possibility of disease enhancement
(Bardina et al., 2017; George et al., 2017; Halstead, 2018; Harri-
son, 2016; Heinz and Stiasny, 2017; Katzelnick et al., 2017; Salje
et al., 2018; Stettler et al., 2016). Passive administration of
monoclonal antibodies represents an alternative approach to
vaccines because human monoclonal antibodies can effectively
neutralize the virus in vitro and protect against ZIKV infection in
mice (Fernandez et al., 2017; Robbiani et al., 2017; Sapparapu
et al., 2016; Stettler et al., 2016; Swanstrom et al., 2016; Yu
et al., 2017). In addition, antibodies can be engineered to prevent
interaction with Fcg receptors that mediate enhancement andorts 25, 1385–1394, November 6, 2018 ª 2018 The Authors. 1385
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. Administration of Z004 Alone Leads to the Emergence of Resistant ZIKV in Rhesus Macaques (Macaca mulatta)
(A) Macaques were administered monoclonal antibody Z004 (red) 1 day before intravenous inoculation with 105 PFU of ZIKV or were untreated (black). The graph
shows plasma viral RNA levels of ZIKV over time as determined by qRT-PCR.
(B) ZIKV mutations emerging in macaques treated with Z004 alone. An alignment in the region of residues E393-K394 (bold) within the EDIII is shown at the top,
and chromatograms of the PCR amplicons showing the mutations (indicated by red arrows) are shown at the bottom. Amino acid changes compared to the
inoculum sequence are highlighted in red. In macaque 6414, E393D and K394R are on separate viral RNAs, as determined by sequencing of the cloned amplicon.
(C) The epitope of ZIKV EDIII recognized by the Z004-related antibody Z006 is shown in red (PDB: 5VIG). The E393-K394 residues are highlighted.
(D) Impaired binding of Z004 to the EDIII escape mutants. ELISA demonstrates reduced binding of Z004 Fab to EDIIIK394R and EDIIIE393D. The positive control
antibody Z015 recognizes an epitope that is independent of the E393 and K394 residues. Data are presented as mean ± SD of triplicates, and a representative of
two experiments is shown.
See also Figure S1.thus minimize the risk of disease enhancement (Beltramello
et al., 2010).
A combination of three antibodies targeting epitopes on the
ZIKV envelope domain II and III regions was recently shown to
be effective at preventing viremia in macaques (Magnani et al.,
2017b), although the same three antibodies in combination failed
to prevent virus transmission to the fetus (Magnani et al., 2018).
Moreover, it was reported that a single antibody to a conforma-
tional epitope prevents ZIKV viremia for 7 days after low-dose
challenge (Abbink et al., 2018), but viremia was not evaluated
for longer periods of time or upon high-dose viral challenge.
Here, we investigate the efficacy of the potent anti-envelope
domain III (EDIII) antibody Z004 (Robbiani et al., 2017) against
high-dose viral challenge in macaques over an extended time
period, as well as molecularly characterize a second human
anti-EDIII monoclonal antibody, Z021, and examine its protec-
tive activity in combination with Z004.1386 Cell Reports 25, 1385–1394, November 6, 2018RESULTS
Z004 is one of several human monoclonal antibodies that were
isolated from an individual with high levels of serum neutralizing
activity against ZIKV (Robbiani et al., 2017). Z004 has strong ac-
tivity against ZIKV and DENV1 in vitro and protects Ifnar1/
mice from lethal ZIKV challenge (Robbiani et al., 2017). To deter-
mine whether Z004 is efficacious against ZIKV in primates, we
administered it to rhesusmacaques 24 hr before high-dose intra-
venous challenge (105 plaque forming units [PFUs]) with a Brazil-
ian strain of ZIKV. Infection wasmonitored by qRT-PCR to detect
viral RNA in the plasma (Figure 1A). All four control animals devel-
oped viremia, which peaked on day 3, with plasma viral loads
ranging from 105 to 107 RNA copies/mL (Figure 1A, black). In
controls, viremia cleared spontaneously beginning on day 6 (Fig-
ure 1A; Coffey et al., 2017). In contrast, the Z004-treated ma-
caques showed delayed and prolonged viremia, with viral loads
Figure 2. Z021 Neutralizes ZIKV and Recognizes a Different Epitope than Z004
(A) Z021 neutralizes ZIKV RVPs corresponding to the African strain. Neutralization by Z004 is shown alongside for comparison. Data are presented asmean ± SD
of triplicates.
(B) Z021 is effective against ZIKV in vitro. ZIKV neutralization was determined bymeasuring the ability of increasing concentrations of Z021 to reduce the number
of plaques in a PRNT assay. Data are presented as mean ± SD of two independent experiments.
(C) Z021 is effective against DENV1 in vitro. DENV1 neutralization was assessed by measuring the relative number of 4G2-positive infected cells by flow
cytometry. Data are presented as mean ± SD of triplicates.
(A–C) Values are relative to control antibody 10-1074. Antibody Z004 is shown alongside for comparison (Robbiani et al., 2017). A representative of two inde-
pendent experiments is shown.
(D–F) Z021 protects mice from ZIKV disease. Layout of the experiment (D). Ifnar1/mice were treated with Z021 or control 10-1074 antibody 1 day before (E) or
1 day after (F) challenge with ZIKV in the footpad (f.p.). Mice were monitored for symptoms and survival. The graph indicates death or symptoms. Survival:
p < 0.0001 (pre-exposure) and p = 0.0002 (post-exposure). Symptoms: p = 0.0002 (pre-exposure) and p = 0.0006 (post-exposure; Mantel-Cox test). The number
of mice used in pre-exposure experiments was 13 (Z021) and 11 (10-1074); for post-exposure experiments, 12 animals were used in each group. Data represent
two combined experiments.
(G) Residues E393-K394 of ZIKV EDIII are not required for Z021 binding. Graphs show ELISA binding to ZIKV EDIII by increasing concentrations of antibody Z004
(left) or Z021 (right) after blocking with wild-type EDIII or EDIIIE393A/K394A.
(H) Residues E393-K394 are not required for ZIKV neutralization by Z021. Graphs show neutralization of ZIKV luciferase RVPs by Z021 and Z004 using wild-
type RVPs (left) or RVPs mutated at the Z004-binding site (E393A-K394A; right). Data are presented as mean ± SD of triplicates, and a representative of two
experiments is plotted. Values are relative to no antibody control.
(legend continued on next page)
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reaching only 33 103 to 53 105 RNA copies/mL (Figure 1A, red).
Thus, Z004 alone alters the course of ZIKV infection and leads to
decreased but prolonged viremia.
To determine whether the viremia in Z004-treated animals was
associated with viral escape mutations, we sequenced the anti-
body target region EDIII of the virus recovered from the plasma of
the treated macaques on days 7 and 10. In both animals, the
circulating viruses contained mutations in the EDIII (K394R in
one animal and E393D or K394R in the other) (Figures 1B
and 1C). Viruses encoding mutations were not observed in the
untreated controls or in the inoculum (data not shown). While
D393 is present in ZIKV strains of African origin, R394 has not
been reported in the Virus Pathogen Resource database
(ViPR; May 24, 2018). ELISA assays using ZIKV EDIIIE393D and
EDIIIK394R mutant proteins confirmed that these mutations inter-
fere with Z004 binding (Figure 1D). In contrast to the macaques,
antibody resistance mutations were rare in Ifnar1/ mice
treated with Z004; nevertheless, the only mouse in a cohort of
eight that developedmutations had the sameK394R substitution
observed in macaques (Figure S1). We conclude that high-dose
intravenous ZIKV challenge in the presence of a single
monoclonal antibody, Z004, leads to selection of resistant viral
mutants.
Z021 is another human monoclonal antibody that, like Z004,
was isolated from an individual with exceptionally high serum
neutralizing activity against ZIKV (Robbiani et al., 2017). Z021
binds to the EDIII of both ZIKV and DENV1, neutralizes ZIKV re-
porter viral particles (RVPs) bearing Asian/American or African
lineage E proteins with a half maximal inhibitory concentration
(IC50) of 1 ng/mL and 0.7 ng/mL, respectively (Figure 2A; Rob-
biani et al., 2017), and has strong activity in plaque reduction
neutralization test (PRNT) using an infectious Puerto Rican strain
of ZIKV (IC50 of 4 ng/mL; Figure 2B). Like Z004, Z021 is also a
potent neutralizer of DENV1 (IC50 of 10.1 ng/mL; Figure 2C).
To determine whether Z021 is effective against ZIKV in vivo,
we administered Z021 to Ifnar1/ mice either 24 hr before
or 24 hr after ZIKV challenge (Figure 2D). Whereas all control
mice developed symptoms and died (n = 11, Figure 2E), only
15% succumbed to infection when Z021 was administered
before infection (n = 13; p = 0.0002 for disease and p < 0.0001
for survival; Figure 2E). Moreover, only 42% developed symp-
toms and 33% succumbed to disease when the antibody was
administered 1 day after infection (n = 12; p = 0.0006 for disease
and p = 0.0002 for survival; Figure 2F). We conclude that Z021 is
efficacious against ZIKV in vitro and protects Ifnar1/ mice
against lethal challenge.
Z004 binding to and neutralization of ZIKV and DENV1 is crit-
ically dependent on ZIKV EDIII residue K394 and also partially
dependent on E393 (DENV1 residues K385 and E384, respec-
tively; Figure 1D; Robbiani et al., 2017). To determine whether
Z004 and Z021 recognize distinct neutralizing epitopes on EDIII,
we performed antigen competition ELISA assays (Figure 2G; see(I) Z004 and Z021 antigen-binding fragments (Fabs) cannot bind to ZIKV EDIII simu
(left) or Z021 IgG (right) and then incubated with a His-tagged Fab of Z021, Z004, o
secondary antibody. The positive control Z015 Fab recognizes an epitope that
presented as mean ± SD of quadruplicates and are representative of two experi
1388 Cell Reports 25, 1385–1394, November 6, 2018STAR Methods). Each monoclonal antibody was incubated with
saturating amounts of either wild-type ZIKV EDIII or an EDIII
bearing mutations in the Z004 target site that interfere with
its binding and neutralizing activity (EDIIIE393A/K394A; Figure 1D;
Robbiani et al., 2017). Residual binding to wild-type EDIII was
then measured by ELISA. Whereas Z004 binding to ZIKV was
only blocked by wild-type ZIKV, binding of Z021 was blocked
by both wild-type and ZIKV EDIIIE393A/K394A, indicating that resi-
dues E393 and K394 are critical for Z004, but not required for
Z021 binding (Figure 2G). In agreement with this finding, Z004
failed to neutralize ZIKV RVPs that were altered to bear the
E393A/K394A mutations while Z021 remained potent against
the mutant RVPs in vitro (Figure 2H). To determine whether the
Z004 and Z021 epitopes overlap, we performed antibody
competition ELISA assays, which showed that the antigen-bind-
ing fragment (Fab) of Z021 did not bind to ZIKV EDIII immobilized
by Z004 immunoglobulin G (IgG), and vice versa (Figure 2I; see
STAR Methods). Thus, Z021 recognizes a neutralizing epitope
on the EDIII that does not require E393-K394 but that is nearby
or overlapping the epitope recognized by Z004.
To gain insight into how Z021 recognizes the Zika and dengue
envelope proteins, we solved crystal structures of Z021 in com-
plex with the EDIII of ZIKV and of DENV1 (Figure 3; Tables S1
and S2) and compared them to the previously obtained struc-
tures of the Z006 and Z004 antibodies in complex with the
same viral antigens (Robbiani et al., 2017). Z021 recognizes
the lateral ridge of ZIKV and DENV1 EDIII and binds to both an-
tigens in a similar orientation (Figure 3A). Although it recognizes
the lateral ridge region of EDIII, Z021 does not bind to the same
epitope as Z004 or the related Z006 but instead recognizes a
distinct but overlapping epitope. When compared to Z004
(when bound to DENV1 EDIII) or Z006 (when bound to ZIKV
EDIII), the Z021 Fab is rotated 45 around an axis near the
complementarity determining region 2 (CDRH2), positioning
the heavy chains in similar regions, while the light chains exhibit
divergent footprints (Figure 3B). Z021 makes heavy- and light-
chain contact to the EDI-EDIII hinge region (the N-terminal end
of the EDIII construct), the BC loop, and the DE loop of ZIKV
EDIII, and heavy chain contacts to the FG loop. Notably, Z021
does not contact E393ZIKV or K394ZIKV, consistent with the
biochemical data indicating that these residues are not required
for Z021 activity (Figure 2). When compared to Z006, Z021
makes additional contacts to the EDI-EDIII hinge region and
DE loops of ZIKV EDIII (Figure 3C). Thus, consistent with the
ELISA and neutralization results (Figure 2), Z021 and Z004
recognize distinct but overlapping epitopes on EDIII.
To determine the efficacy of the combination of Z004 and
Z021 against high-dose intravenous challenge with ZIKV, we
co-administered the two antibodies to macaques 24 hr before
infection. All three macaques developed delayed infections
with low levels of viremia that peaked at 102–103 RNA copies/
mL (Figures 4A and 4B). In contrast to macaques treated withltaneously. ZIKV EDIII antigenwas immobilized in an ELISAwith either Z004 IgG
r Z015. Fab binding to the IgG-immobilized ZIKV EDIII was detected by anti-His
is distinct from that of both Z021 and Z004 (Robbiani et al., 2017). Data are
ments.
Figure 3. Comparison of Z021 and the Z004-
Related Antibody, Z006, Binding to the ZIKV
and DENV1 EDIII Domain
(A) Superimposition of the Z021 Fab-ZIKV complex
with the Z021 Fab-DENV1 complex. The EDI-EDIII
hinge region and loops of the ZIKV EDIII (bright
colors) and DENV1 EDIII (light colors) within the
epitope are highlighted, and the side chains of
E394 and K395 residues of ZIKV are shown in
sticks. The two views are related by a 90 rotation.
(B) Superimposition of Z021 Fab-ZIKV EDIII
complex with Z006 Fab-ZIKV EDIII complex (PDB:
5VIG). The VHVL of Z021 Fab is rotated 45
around an axis near CDRH2 compared to the Z006
VHVL bound to the same antigen.
(C) The epitopes of Z021 and Z006 on ZIKV EDIII
are overlapping but distinct. EDIII residues within
4 A˚ of Z021 Fab (blue), Z006 Fab (red), or both
(purple) are highlighted on a surface representation
of the ZIKV EDIII from the Z021-ZIKV EDIII complex
structure. The E393-K394ZIKV motif is outlined. The
two views are related by a 90 rotation.
See also Tables S1 and S2.Z004 alone (Figure 1), there were no mutations in the EDIII target
site of the two antibodies (data not shown).
Late occurrence of viremia in some animals was not a conse-
quence of rapid clearance of Z004 and Z021, since high levels of
human antibodies were detectable in the macaque plasma (Fig-
ure S2). Similar results were obtained with Z004 and Z021 Fc
mutant antibodies (GRLR) that are unable to mediate enhance-
ment but maintain antiviral efficacy in vitro and in mice (Figures
S3 and S4): peak viral loads were comparable between wild-
type and GRLR treated macaques (brown and green bars in Fig-
ure 4B) and no EDIII mutations were detected in either group.
Although a trend for delayed peak viremia was observed in the
macaques receiving the combination of wild-type antibodies
(mean of 11 days versus 4 days inmacaques receiving GRLR an-Cell Repotibodies), this difference is not statistically
significant (p = 0.2; Figure 4A). Notably, in
contrast to the macaques that received
Z004 + Z021, plasma from macaques
treated with Z004+Z021 (GRLR) anti-
bodies did not enhance infection in vitro
(Figure 4C). A K294R mutation, which is
outside of the EDIII region targeted by
the antibodies, was detected in one of
the emerging viruses; however, RVPs
containing K294R remained sensitive to
both Z004 and Z021, suggesting that
this is not a resistance mutation (Fig-
ure S4D). Thus, treatment of non-human
primates with the combination of Z004
and Z021, two antibodies that target
distinct but overlapping epitopes on the
EDIII lateral ridge, suppresses and delays
viremia in macaques infected intrave-
nously with a high dose of ZIKV. More-
over, the combination of two antibodiesprevents the emergence of ZIKV escape variants. Finally, anti-
bodies whose Fc region is engineered to prevent enhancement
provide similar levels of protection as antibodies with a wild-
type Fc region.
DISCUSSION
We have determined the molecular mechanism of antigen bind-
ing by Z021 (this work) and Z004 (Robbiani et al., 2017), two
potent neutralizing monoclonal antibodies against ZIKV and
DENV1, and established that in combination, they prevent viral
escape mutations in non-human primates.
It has been difficult to develop vaccines against the four DENV
serotypes because of the complications associated with diseaserts 25, 1385–1394, November 6, 2018 1389
Figure 4. TheCombination of Z004 and Z021
Antibodies Protects ZIKV-Challenged Ma-
caques
(A) Macaques were administered a combination of
Z004 and Z021 (brown) or a combination of the
same antibodies containing mutations in the Fc
that prevent Fcg receptor binding (Z004-GRLR
and Z021-GRLR; green) 1 day before intravenous
inoculation with 105 PFU of ZIKV. The graph shows
plasma viral RNA levels of ZIKV over time as
determined by qRT-PCR. Untreated controls are
the same as in Figure 1.
(B) Peak viral RNA loads in plasma are decreased
by antibody treatment (based on Figures 1A and
4A). The p value was determined with the Mann-
Whitney test. The gray bar represents the peak
viral load of both Z004 + Z021 and Z004 + Z021
(GRLR) groups combined.
(C) Plasma of macaques treated with the combi-
nation of Z004-GRLR and Z021-GRLR fails to
induce antibody-dependent enhancement (ADE)
of infection in K-562 cells by ZIKV RVPs. Dilutions
of macaque plasma (1:50–1:328,050; 9 dilutions in
total) obtained at different time points were as-
sayed for the ability to induce ZIKV RVP infection
(see STAR Methods). n.d., not determined due to
lack of plasma sample.
See also Figures S2–S4.enhancement by cross-reactive antibodies (de Silva and Harris,
2018; Halstead, 2018; Screaton and Mongkolsapaya, 2018;
Whitehead and Subbarao, 2018). ZIKV antibodies can cross-
react with DENV and cause DENV enhancement in animal
models. Therefore, it is anticipated that developing safe and
effective ZIKV vaccinesmay be challenging (Andrade and Harris,
2018; George et al., 2017; Stettler et al., 2016).
Moreover, flaviviruses are RNA viruses that undergo high rates
of error-prone replication, producing mutant variants that can be
selected for resistance (Diamond, 2003; Drake et al., 1998; Elena
et al., 2000). Indeed, resistant viral variants arise in antibody-
containing cell cultures infected with DENV (Lin et al., 1994;
Lok et al., 2001; Zou et al., 2012), WNV (Beasley and Barrett,
2002; Chambers et al., 1998), YFV (Daffis et al., 2005), Japanese
encephalitis virus (Shimoda et al., 2013), tick-borne encephalitis
virus (Holzmann et al., 1989), and ZIKV (Wang et al., 2017a).
Resistance to monoclonal antibodies has also been docu-1390 Cell Reports 25, 1385–1394, November 6, 2018mented in mice challenged with WNV
(Sapkal et al., 2011) and rhesus ma-
caques challenged with high doses of
DENV (Lai et al., 2007; Magnani et al.,
2017a). Our experiments are consistent
with these earlier observations and
extend them to ZIKV in non-human pri-
mates by showing that administration of
a single antibody leads to the selection
of resistant viruses.
To test the hypothesis that two anti-
bodies might be more effective than
one, we molecularly characterized Z021.
Structural analysis of Z021 and compari-son to Z004 (and related Z006) revealed that the two antibodies
target overlapping but distinct sites. Z021 contacts the EDI-EDIII
hinge region of ZIKV and DENV1 EDIII with both its heavy and
light chains, while Z004 and Z006makemore extensive contacts
to the FG loop, including the E393-K394ZIKV motif (E384-
K385DENV1). Because the E393-K394ZIKV motif is peripheral to
the Z021 epitope, viruses with mutations at these positions are
likely to remain sensitive to Z021. These differences probably ac-
count for the efficacy of this combination of two antibodies
despite the similarities in their target sites.
In high-dose challenge experiments, the combination of
two monoclonal antibodies further decreased peak viremia
compared to Z004 alone (Figure 4B). The antiviral effects of the
antibodies were independent of their ability to bind to Fcg recep-
tors or to enhance infection in vitro. However, in contrast to pro-
phylaxis with Z004 alone, where resistant variants were detected
in both treated animals, there were no viral escape mutants in
any of the six macaques treated with the combination of Z004
and Z021. Thus, the combination of these two antibodies is
advantageous over Z004 alone due to their ability to prevent viral
escape.
Z004 and Z021 target the EDIII lateral ridge, which is one of the
key sites of viral attachment to cells, and both block infection
in vitro. However, they do not provide sterile protection, despite
high levels in circulation. One potential explanation for the
disparity between in vitro and in vivo results is that ZIKV can atta-
ch to and infect cells through a number of different receptors,
some of which may not be present in the Huh-7.5 cells used to
measure infectivity in vitro (Heinz and Stiasny, 2017; Miner and
Diamond, 2017). For example, virus attachment and entry via
these receptors could be mediated through epitopes outside
of the EDIII lateral ridge targeted by Z004 and Z021. Finally,
viremia was delayed in 5 of the 8 treatedmacaques; an intriguing
hypothesis is that during this time, ZIKV resides in and replicates
in immune-privileged sites such as brain and testes that cannot
be reached by antibodies (Iwasaki, 2017; Mital et al., 2011).
Our results differ from experiments where a single monoclonal
was protective against low-dose subcutaneous ZIKV challenge
(Abbink et al., 2018). The difference may be due to a 100-fold
higher infectious dose of ZIKV delivered intravenously in our ex-
periments. An additional possibility is that the animals in the low-
dose experiments were onlymonitored for 7 days, whichmay not
have been sufficient to document delayed infection seen after
antibody treatment (Abbink et al., 2018). Whether other anti-
bodies, single or in combination, will be completely protective af-
ter high-dose challenge remains to be determined but would be
highly relevant for further clinical development, since the precise
dose delivered by the Aedes aegypti vector is not known (Abbink
et al., 2018; Magnani et al., 2017b).
Antibodies induced by vaccination or infection with any one of
the DENV serotypes may fail to neutralize a second serotype and
instead enhance dengue disease, with potentially catastrophic
consequences. It is possible that dengue enhancement would
also be mediated by cross-reactive antibodies elicited by vacci-
nation against ZIKV (Andrade and Harris, 2018; George et al.,
2017; Stettler et al., 2016). Because of this uncertainty, passive
antibody administration for protection against ZIKV may repre-
sent a safe and practical alternative to vaccination during preg-
nancy and for infants and travelers, since antibodies can be en-
gineered to prevent enhancement and have greatly extended
half-lives by incorporating known Fc mutations (Gautam et al.,
2018; Griffin et al., 2017; Ko et al., 2014; Robbie et al., 2013;
Zalevsky et al., 2010) (https://www.clinicaltrials.gov identifier
NCT02878330). Our observations indicate that a combination
of two antibodies targeting the EDIII lateral ridge is not sufficient
for complete protection of high-dose ZIKV challenge, and com-
binations of additional antibodies are likely required.STAR+METHODS
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pZIKV/HPF/CprME Laboratory of T. Pierson N/A
pZIKV/HPF/CprM*E* Robbiani et al., 2017 N/A
Wild type ZIKV EDIII expression vector Robbiani et al., 2017 N/A
Software and Algorithms
Prism (v7) GraphPad https://www.graphpad.com
Mosflm (v7.2.1, part of CCP4 package) Battye et al., 2011 http://www.ccp4.ac.uk
CCP4 (v7.0.032) Winn et al., 2011 http://www.ccp4.ac.uk
Phenix (v1.11.1-2575) Adams et al., 2010 http://www.phenix-online.org
Coot (v0.8.7, part of CCP4 package) Emsley and Cowtan, 2004 http://www.ccp4.ac.uk
AntibodyDatabase (v1.0) West et al., 2013 N/A
BIAcore T200 evaluation software GE Healhcare http://www.biacore.com/lifesciences/
index.html
Other
Biacore T200 SPR system GE Healthcare CAT#:28975001
CM5 sensor chip GE Healthcare CAT#:BR100399CONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for reagents should be directed to and will be fulfilled by the Lead Contact, Davide Robbiani
(drobbiani@rockefeller.edu). Sharing of reagents may require UBMTA agreements.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Macaques
Rhesusmacaques (Macacamulatta) were healthy juveniles or adults from the conventional type D retrovirus-free, SIV-free and simian
lymphocyte tropic virus type 1 antibody negative colony at the California National Primate Research Center (CNPRC). All animals
were males except for two of the untreated controls (5021 and 5242). Animals were also confirmed to be antibody negative for
West Nile virus. Animals were housed in accordance with Association for Assessment and Accreditation of Laboratory Animal
Care Standards. We strictly adhered to Guide for the Care and Use of Laboratory Animals prepared by the Institute for Laboratory
Animal Research. The study was approved by the Institutional Animal Care and Use Committee of the University of California Davis.
When necessary for inoculations or sample collections, macaques were immobilized with 10 mg/kg ketamine hydrochloride (Parke-
Davis) injected intramuscularly after overnight fasting. Z004 and Z021 antibodies were administered to macaques at doses of
15 mg/kg body weight each by slow intravenous (i.v.) infusion (2ml/minute) 24 hours before saphenous vein i.v. inoculation with Bra-
zilian ZIKV (105 PFU in 1mL of RPMI-1640medium). Macaques were evaluated twice daily for clinical signs of disease including poor
appetence, stool quality, dehydration, diarrhea, and inactivity. None of the animals that received the antibodies developed any clin-
ical signs, suggesting a good safety profile. In contrast, one of four untreated macaques developed a severe transient skin rash in the
axillary and inguinal areas on day 6, which peaked on day 8, was treated with topical antibiotics and steroids, and rapidly improved
from day 10 onward. Animals were sedated for antibody administration (minus 24h), at time zero (virus inoculation), daily for 7 to
8 days, and then every few days for sample collection. EDTA-anti-coagulated blood samples were collected using venipuncture.e2 Cell Reports 25, 1385–1394.e1–e7, November 6, 2018
Mice
Interferon-ab receptor knock-out mice were obtained from The Jackson Laboratory (Ifnar1/; B6.129S2-Ifnar1tm1Agt/Mmjax) and
were bred and maintained in the animal facility at Rockefeller University. Mice were specific pathogen free and on a standard
chow diet. Both male and female mice (3-4 week old) were used for experiments and were equally distributed within experimental
and control groups. 125 mg of monoclonal antibodies in 200 mL of PBS were administered intraperitoneally to Ifnar1/ mice one
day before or one day after footpad infection with 1.25x105 plaque forming units (PFU) of ZIKV Puerto Rican strain in 50 ml. Mice
were monitored for symptoms and survival over time. Animal protocols were in agreement with NIH guidelines and approved by
the Rockefeller University Institutional Animal Care and Use Committee.
Cell lines
Human embryonic kidney HEK293-6E suspension cells were cultured at 37C in 8% CO2, shaking at 120 rpm. All other cell lines
described below were cultured at 37C in 5%CO2, without shaking. Green monkey Vero cells and human hepatocytes Huh-7.5 cells
(Blight et al., 2002) were cultured in Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 1% nonessential amino acids
(NEAA) and 5% FBS. Human Lenti-X 293T cells and STAT1/, an SV40 large T antigen immortalized skin fibroblast line (Chapgier
et al., 2006), were grown in DMEM 10% FBS. K-562 cells were maintained in RPMI supplemented with 10% FBS (ATCC, CCL-243).
Huh-7.5 cells were developed in the Laboratory of Virology and Infectious Disease at Rockefeller University and verified by STR (stan-
dard tandem repeat). A seed-lot system is in place for these highly utilized cell lines, as well as for other lines obtained from the ATCC.
The ATCC implements cell line authentication by STR DNA profiling. STAT1/ cells are of unknown sex; HEK293-6E, Lenti-X 293T,
K-562 and Vero are of female origin; Huh-7.5 are male.
Viruses
For in vitro experiments, ZIKV 2015 Puerto Rican PRVABC59 (Lanciotti et al., 2016) was obtained from the CDC and passaged twice
in human Huh-7.5 cells, and the Thai isolate of DENV1 PUO-359 (TVP-1140) was obtained from Robert Tesh and amplified by three
passages in C6/36 insect cells. Formouse experiments, ZIKV 2015 Puerto Rican PRVABC59was passaged once in STAT1/ human
fibroblasts. For macaque experiments, a 2015 isolate of ZIKV fromBrazil (strain SPH2015; GenBank accession number KU321639.1)
was used. The strain was isolated from the plasma of a transfusion recipient and was passaged twice in VERO cells. Virus titrations
were performed in African GreenMonkey Kidney (VERO) cells using plaque assays. For PRVABC59, 200 mL of 10-fold serial dilutions
of virus in OPTI-MEM were used to infect 400,000 cells seeded the previous day in a 6-well format. After 90 minutes adsorption, the
cells were overlayedwith DMEMcontaining 2%FBSwith 1.2%Avicel and Penicilin/Streptomycin. Four days later the cells were fixed
with 3.5% formaldehyde and stained with crystal violet for plaque enumeration. For SPH2015, 250 mL of 10-fold serial dilutions of
samples in DMEM were inoculated onto confluent cell monolayers in duplicate in 6-well plates. After 60 minutes adsorption at
37C, the cells were overlayed with MEM containing 2% FBS with 1.0% Penicilin/Streptomycin in 0.8% agar (liquefied 10% agar,
ultrapure agarose [Invitrogen] diluted in 42C MEM) and allowed to solidify, and incubated at 37C with 5% carbon dioxide for
8 days. Cell monolayers were then fixed with 4% formalin for 30 minutes, agar plugs were removed, and 0.025% gentian violet
(Sigma) in 30%ethanol was overlaid in eachwell to stain viable cells. Viral titers were recorded as the reciprocal of the highest dilution
where plaques are noted. The limit of detection of the assay was 1.6 log10 PFU/ml (Coffey et al., 2017; Robbiani et al., 2017).
METHOD DETAILS
Production of antibodies and Fabs
Z021, Z004, Z015 (Robbiani et al., 2017) and 10-1074 (Mouquet et al., 2012) were prepared by transient transfection of mammalian
HEK293-6E cells with equal amounts of immunoglobulin heavy and light chain expression vectors. The supernatant was harvested
after seven days and the antibodies purified using Protein G Sepharose 4 Fast Flow. LPS was removed with TritonX-114 and the an-
tibodies concentrated to 4.6 to 19 mg/ml in PBS. The GRLR (Horton et al., 2008; Lu et al., 2016), LS (Ko et al., 2014; Zalevsky et al.,
2010) and combined (GRLR/LS) modifications in the Fc portion of Z004 and Z021 human IgG1 expression plasmids (Tiller et al., 2008)
were generated with Q5 site-directed mutagenesis kit (New England Biolabs) according to the company’s instructions and with the
primers listed in Table S3. Fabs expressed for crystallography were expressed by transient transfection of HEK293-6E mammalian
cells with equal amounts of C-terminally His-tagged Fab heavy chain (VH-CH1) and light chain expression vectors. The supernatant
was harvested after six days and the Fabs were purified by affinity purification using HisTrap HP columns (GE Healthcare Life
Sciences). Proteins were eluted with 300mM imidazole and then concentrated and further purified by size exclusion chromatography
on a Superdex 200 Increase column (GE Healthcare Life Sciences).
Production of ZIKV proteins
Expression plasmids encoding the ZIKV mutant proteins EDIIIE393A/K394A, EDIIIE393D and EDIIIK394R were generated by modifying the
wild-type EDIII expression plasmid (Robbiani et al., 2017) using QuikChange site-directed mutagenesis (Agilent Technologies) and
confirmed by DNA sequencing. Primers used for mutagenesis are listed in Table S3. Mutant ZIKV EDIII proteins were expressed in
E. coli BL21(DE3) (New England Biolabs), refolded from inclusion bodies, and purified (Robbiani et al., 2017; Sapparapu et al., 2016).
Briefly, upon transformation with an appropriate EDIII protein-encoding expression vector, cells were grown to mid-log phase andCell Reports 25, 1385–1394.e1–e7, November 6, 2018 e3
induced with isopropyl b-D-1-thiogalactopyranoside (IPTG) for 4 hours. Upon lysis, the insoluble fraction containing the inclusion
bodies was solubilized in buffer containing 6M guanidine hydrochloride, 100mM Tris-HCl pH 8.0, and 20mM b-mercaptoethanol
and clarified by centrifugation. The solubilized inclusion bodies were then refolded using rapid dilution into 400 mM L-arginine,
100mM Tris-HCl (pH 8.0), 2 mMEDTA, and 5 and 0.5 mM reduced and oxidized glutathione at 4C. The refolded protein was filtered,
concentrated, and finally purified by size exclusion chromatography (Superdex 75; GE Healthcare) in 20mM Tris pH 8.0, 150mM
NaCl, 0.02% NaN3.
Generation and production of RVPs
Wild-type ZIKV Reporter Viral Particles (RVPs) with E proteins corresponding to Asian/American or African lineage were previously
reported (Robbiani et al., 2017). Plasmids for expression of ZIKV CprME with E mutations were generated from plasmid pZIKV/HPF/
CprM*E* (Robbiani et al., 2017), a derivative of pZIKV/HPF/CprME, a ZIKV C-prM-E expression construct provided by Ted Pierson
(NIH) and engineered to contain unique BspHI and SacII restriction sites flanking the envelope region, allowing facile manipulation.
Assembly PCR-based site-directed mutagenesis was used to introduce the E393A-K394A double mutation or K294R single
mutation into the envelope of ZIKV H/PF/2013 in pZIKV/HPF/CprM*E*, resulting in plasmids pZIKV/HPF/CprM*E*(E393A-K394A)
or pZIKV/HPF/CprM*E*(K294R), respectively. The primers used for assembly PCR and mutagenesis are listed in Table S3. All
PCR-derived plasmid regions were verified by sequencing.
RVPs bearing the ZIKV E protein with E393A-K394A or with K294R mutations were generated by cotransfection of Lenti-X-293T
cells with plasmids pZIKV/HPF/CprM*E*(E393A-K394A) or pZIKV/HPF/CprM*E*(K294R) with pWNVII-Rep-REN-IB (Pierson et al.,
2006; Robbiani et al., 2017). One mg of pWNVII-Rep-REN-IB (WNV replicon expression construct) and 3 mg of the appropriate
flavivirus CprME expression plasmid were co-transfected with Lipofectamine 2000 (Invitrogen) according to the manufacturer’s
instructions. Lipid–DNA complexes were replaced after 4–5 h incubation with DMEM containing 20 mM HEPES and 10% FBS. After
48-72 h incubation at 34C, RVP-containing supernatants were harvested, filtered through a 0.45 micron filter and frozen at 80C.
In vitro neutralization and ADE assays
Plaque reduction neutralization test (PRNT) with ZIKV PRVABC59, and flow cytometry-based neutralization assay with DENV1 PUO-
359 were used to measure antibody neutralization activity in VERO cells (Robbiani et al., 2017). For ZIKV, diluent medium was
Medium 199 (Lonza) supplemented with 1% BSA and Pen/Strep (BA-1 diluent). Briefly, 3- to 10-fold serial human antibody dilutions
were added to a constant amount of Huh-7.5-ZIKV stock diluted in BA-1 diluent and incubated for 1 h at 37C prior to application to
VERO cells seeded at 400,000 cells per 6-well the day prior. After 90 minutes adsorption, the cells were overlayed with DMEM con-
taining 2%FBSwith 1.2%Avicel and Pen/Strep. Four days later the cells were fixed with 3.5% formaldehyde and stained with crystal
violet for plaque enumeration. PRNT50 values were determined as the antibody concentration that resulted in 50% of the number of
plaques obtained with the no antibody control. For DENV1, 5,000 VERO cells were seeded in 96-well plates. The next day, serial di-
lutions of antibody were incubated with DENV1 for 1 hr at 37C and applied to the cells (MOI = 0.02). After 3 days, the cells were fixed
with 2% formaldehyde and stained with the pan flavivirus anti-E protein 4G2 monoclonal antibody (2 mg/ml) in PBS containing 1%
FBS and 0.5% saponin. Bound antibody was detected with Alexa Fluor 488-conjugated anti-mouse IgG antibody (1:1,000,
Invitrogen) and the percentage of infected cells determined by flow cytometry. Percentages of cells infected with DENV1 in the
presence of the different concentrations of antibody compared to cells infected with DENV1 in the absence of antibody was used
to estimate the 50% reduction.
Neutralization of luciferase-encoding RVPs by antibodies using the ZIKV wild-type, E393A-K394A, K294R, and African mutant
RVPs was performed with Huh-7.5 cells. 15,000 cells were seeded in each well of a 96-well plate the day before infection in a volume
of 100 ml. RVPs were diluted in BA-diluent, and 100 mL were added to 100 mL of triplicate samples of 3- or 10-fold serially diluted
human antibody. After incubation for 1 h at 37C, 100 mL of the RVP/antibody mixture was added to the cells. After 24 h incubation
at 37C, the medium was removed and cells were lysed in 75 mL lysis buffer and 20 mL used for Renilla luciferase measurement using
the Renilla Luciferase Assay System (Promega) according to the manufacturer’s instructions and read using a FLUOstar Omega
luminometer (BMG LabTech). Neutralization capacity of the antibody was determined by the percentage of luciferase activity
obtained relative to activity from RVPs incubated with BA-diluent alone (no antibody). Antibody dependent enhancement (ADE) of
infection assays using antibodies or macaque plasma were similar to neutralization assays with RVPs, except that Fc-receptor
bearing K-562 cells were used, and that the cells were in 96-well plates coated with 0.01% poly-L-lysine (Sigma). The macaque
plasma was serially diluted 1:3 in BA-1 medium (1:50 – 1:328050, 9 dilutions in total). BA-1 medium is Medium 199 (Lonza,
12-109F) supplementedwith 1%BSA, 1400mg/L sodium bicarbonate and 100U/ml Pen/Strep. The luciferase signal was normalized
to the signal obtained with 10ng/ml of antibody Z004, which was present on the same plate.
ELISA assays
Fab ELISA
Figure 1D. 5 mg/mL ZIKV EDIII antigen (EDIIIwild-type, EDIIIE393A/K394A, EDIIIE393D or EDIIIK394R) was adsorbed to a NuncMaxiSorp 384-
well ELISA plate overnight at 4C. The ELISA plate was blocked with 3% BSA in TRIS buffered saline with 0.05% Tween-20 (TBS–T),e4 Cell Reports 25, 1385–1394.e1–e7, November 6, 2018
washed with TBS-T, and then serial dilutions of Fab were added and incubated for 3 hours at room temperature. After washing the
plate with TBS-T, bound Fab was detected using goat-anti-human IgG-HRP (GenScript; 1 hour, room temperature) and developed
with SuperSignal ELISA Femto Substrate (Thermo Fisher).
Antigen competition ELISA
Figure 2G. Serial dilutions of Z004 or Z021 antibody were incubated overnight with nutation at 4C in V-bottom 96-well plates in
the presence of saturating concentrations of either wild-type EDIII, EDIIIE393A/K394A, or no protein control. In preliminary experiments,
the saturating concentration of EDIII protein was determined as being approximately 1 mg/ml, and was increased to 10 mg/ml for the
actual experiment. After overnight incubation the samples were added to ELISA plates that had been pre-coated with wild-type EDIII
and the residual antibody binding to EDIII was detected using HRP-conjugated goat anti-human IgG (Jackson ImmunoResearch;
1 hour, room temperature). The signal was enhanced by two amplification steps. First, after incubating with goat anti-human
IgG-HRP (Jackson ImmunoResearch; 1 hour, room temperature) and washing with PBS containing Tween-20 0.05%, anti-goat
IgG-biotin was added (Jackson ImmunoResearch; 1 hour, room temperature). Second, after washing, streptavidin-HRP was added
(Jackson ImmunoResearch; 1 hour, room temperature). After the final washes, the reaction was developed with ABTS substrate (Life
Technologies).
Antibody competition ELISA
Figure 2I. Z004 or Z021 IgG (5 mg/mL) was adsorbed overnight at 4C in a NuncMaxiSorp 384-well ELISA plate. The ELISA plate was
blockedwith 3%bovine serum albumin (BSA) in TBS–T, and then 5 mg/mL of ZIKV EDIII was added and incubated for 3 hours at room
temperature. The plate was washed with TBS-T to remove excess antigen, and Fab was then added at 25 mg/mL and incubated
for 3 hours at room temperature. Bound His-tagged Fab was detected using THE His Tag Antibody (Genscript; 1 hour, room
temperature), followed by goat-anti mouse IgG-HRP (Jackson ImmunoResearch; 1 hour, room temperature), and developed with
SuperSignal ELISA Femto Substrate (Thermo Fisher). Relative light units were plotted for each IgG-antigen pair.
ELISA for human IgG detection in macaque
Figure S2. Neutravidin (ThermoScientific; 2 mg/ml in PBS) was absorbed to high binding 96-well plates for overnight at 4C. After
washing the plate using PBS with 0.05% Tween-20 (PBS-T), the biotinylated anti-human IgG capture antibody was added
(ThermoScientific; 2 mg/ml in PBS-T, 1 hour at room temperature). Upon washes, the plates were blocked with 2% BSA in PBS-T
(2 hours at room temperature), blotted, and then serial dilutions of the macaque plasma were added to the wells (5 steps of
1:4 dilutions in PBS-T, starting with 1:10). Each plate included serial dilutions of the standard, in duplicates (Z004 IgG, 11 steps of
1:3 dilutions in PBS-T, starting with 10 mg/ml). Plates were incubated for 1 hour at room temperature and washed prior to adding
the detection reagent anti-human IgG-HRP (Jackson Immunoresearch; 1 hour at room temperature). After the final washes, the
reaction was developed with ABTS substrate (Life Technologies).
Surface plasmon resonance
FcgR and FcRn binding affinity of the Z004 Fc domain variants was determined by surface plasmon resonance (SPR) (Li et al., 2017;
Wang et al., 2017b). Briefly, all experiments were performed on a Biacore T200 SPR system (GE Healthcare) at 25C in HBS-EP+
buffer (GE Healthcare; pH 7.4 for FcgRs, pH 6.0 for FcRn). Recombinant protein G (Thermo Fisher) was immobilized to the surface
of a CM5 sensor chip (GE Healthcare) using amine coupling chemistry at a density of 500 resonance units (RU). Fc variants of the
Z004 antibody were captured on the Protein G-coupled surface (250 nM injected for 60 s at 20 ml/min) and recombinant human
FcgR ectodomains (7.8125 – 2000 nM; Sinobiological) or FcRn/b2 microglobulin (1.95 – 500 nM; Sinobiological) were injected
through flow cells at a flow rate of 20 ml/min. Association timewas 60 s followed by a 600 s dissociation step. At the end of each cycle,
the sensor surface was regenerated with 10 mM glycine, pH 2.0 (50 ml/min; 40 s). Background binding to blank immobilized flow cells
was subtracted and affinity constants were calculated using BIAcore T200 evaluation software (GE Healthcare) using the 1:1 Lang-
muir binding model.
Processing of macaque blood samples
EDTA-anticoagulated blood was processed immediately by centrifugation for 10 minutes at 800 X g to separate plasma from cells.
The plasmawas spun an additional 10minutes at 800 X g to further remove cells, and aliquots were immediately frozen at80C. The
cellular blood fraction was diluted with PBS and layered on lymphocyte separation medium (MP Biomedicals) and spun for 30 m at
800 g to isolate peripheral blood mononuclear cells that were washed and then cryopreserved for future analyses. Complete blood
counts (CBC) were performed on EDTA-anticoagulated blood samples; samples were analyzed using a Pentra 60C+ analyzer (ABX
Diagnostics); differential counts were determined manually using Wright-Giemsa staining.
Isolation and quantitation of viral RNA
Zika virus RNA was isolated from plasma and measured by RT-qPCR according to methods described previously (Lanciotti et al.,
2008) and detailed below, which were modified to increase the initial volume of sample tested from 140 to 300 mL (when available)
to increase sensitivity. RNAwas extracted from plasma according tomanufacturer’s recommendations using an Applied Biosystems
MagMax 96-well Viral RNA kit and the AM1836 DW200 STD program on a MagMax Express 96-Deep Well Magnetic Particle
Processor (ThermoFisher, Waltham, MA). All RNA extracts were eluted in 60 mL of DEPC-treated water for storage at 80C prior
to quantification. ZIKV RNA was measured in triplicate by reverse transcription RT-qPCR on an Applied Biosystems ViiA 7 machineCell Reports 25, 1385–1394.e1–e7, November 6, 2018 e5
using the Taqman Fast Virus 1-Step Master Mix (Thermo) and published primers (ZIKV 1086, ZIKV 1162c, and ZIKV 1107-FAM;
(Lanciotti et al., 2008)) with 9.6 mL of RNA. Levels of ZIKV RNA in samples are expressed as mean log10 copies per ml plasma.
Virus sequencing
For detection of virus escape mutations in macaques, ZIKV RNA was extracted at peak viremia from plasma using the Qiaamp viral
RNAmini kit following themanufacturer’s recommendations with elution of RNA inwater. QIAGENOne-Step RT-PCRwas performed
using either of two primer sets targeting sequences surrounding the ZIKV EDIII region (see Table S3), with 50C for 30 m, 95C for
15m. Next, 40 cycles of each of the 3 stepswere performed: 94C for 1m, 58C for 1m, 72C for 1m15s, followed by final extension of
72C for 10 m. RT-PCR amplicons were visualized on 1% agarose gels stained with ethidium bromide and sequenced after
purification using the Qiaquick PCR purification kit. Sequences were called based on clean chromatograms sequenced with the
primers used for amplification. Due to very low levels of viremia, reliable EDIII sequence information was obtained for only
210 out of 303 nucleotides from macaque 6082 (Z004+Z021), and no sequencing was possible from macaque 6146 (Z004+Z021
GRLR). Viral sequences in mice were from blood. RNA was extracted from TRIzol-LS (Life Technologies) and reverse transcribed
with Superscript III RT (Thermo Fisher Scientific) and random primers according to the company’s protocol prior to PCR amplification
of the ZIKV EDIII region with primers DFRp1284 and DFRp1469 followed by PCR clean-up with Nucleospin (Macherey-Nagel)
and direct sequencing with primer DFRp1283. Where necessary, a second round of nested PCR was performed with primers
DFRp1472 and DFRp1470. The primers sequence is listed in Table S3.
Crystallization and structure determination
Z021-ZIKV EDIII complex
The complex for crystallization was produced bymixing Z021 Fab and ZIKV EDIII at a 1:1 molar ratio, incubating at room temperature
for 1-2 hours, and concentrating to 14.1 mg/mL. Crystals of Z021 Fab–ZIKV EDIII complex (space group P212121; a = 73.88 A˚,
b = 105.62 A˚, c = 107.24 A˚; one molecule per asymmetric unit) were obtained by combining 0.2 mL of protein complex with 0.2 mL
of 0.1M HEPES pH 7.0, 29% PEG 1000 in sitting drops at 22C. Crystals were cryoprotected with 25% glycerol.
X-ray diffraction data were collected at Advanced Photon Source (APS) beamline 23-ID-D using a Dectris Pilatus 6M detector. The
data were integrated using Mosflm (Battye et al., 2011) and scaled using CCP4 (Winn et al., 2011). The Z021-ZIKV EDIII complex
structure was solved by molecular replacement using the VHVL and CHCL domains from our Z021-DENV1 EDIII complex and ZIKV
EDIII from PDB 5KVG as search models in Phenix (Adams et al., 2010). The model was refined to 2.48 A˚ resolution using an iterative
approach involving refinement in Phenix and manual rebuilding into a simulated annealing composite omit map using Coot (Emsley
and Cowtan, 2004). The final model (Rwork = 18.2%; Rfree = 22.8%) contains 537 protein residues and 68 water molecules. 96%, 4%,
and 0.2% of the protein residues were in the favored, allowed, and outlier regions, respectively, of the Ramachandran plot. Residues
that are disordered and not included in the model are: HC residues 216-219 and the 6X His tag; LC residue 214, and ZIKV EDIII
residues 299-302 and 405-407. The accession number for the Z021-ZIKV EDIII complex crystal structure reported in this paper is
PDB: 6DFI.
Z021-DENV1 EDIII complex
The complex for crystallization was produced by mixing Z021 Fab and DENV1 EDIII at a 1:1 molar ratio, incubating at room temper-
ature for 1-2 hours, and concentrating to 12.25mg/mL. Crystals of Z021 Fab–DENV1 EDIII complex (space group C2221; a = 60.54 A˚,
b = 91.60 A˚, c = 187.14 A˚; one molecule per asymmetric unit) were obtained by combining 0.2 mL of protein complex with 0.2 mL of
0.1M sodium citrate pH 4.8, 28%Jeffamine ED-2001 pH 7.0 in sitting drops at 22C.Crystals were cryoprotectedwith Fomblin Y oil.
X-ray diffraction data were collected at Stanford Synchrotron Radiation Lightsource (SSRL) beamline 12-2 using a Dectris Pilatus
6Mdetector. The data were integrated usingMosflm (Battye et al., 2011) and scaled using CCP4 (Winn et al., 2011). The Z021-DENV1
EDIII complex structure was solved by molecular replacement using the VHVL and CHCL domains from PDB 4YK4 and DENV1 EDIII
from PDB 4L5F as search models in Phenix (Adams et al., 2010). The model was refined to 2.07 A˚ resolution using an iterative
approach involving refinement in Phenix and manual rebuilding into a simulated annealing composite omit map using Coot (Emsley
and Cowtan, 2004). The final model (Rwork = 18.4%; Rfree = 23.2%) contains 532 protein residues and 126water molecules. 96%, 4%,
and 0% of the protein residues were in the favored, allowed, and disallowed regions, respectively, of the Ramachandran plot.
Residues that are disordered and not included in the model are: HC residues 215-219 and the 6X His tag; LC residues 213-214.
The Z021-DENV1 EDIII complex crystal structure has been deposited in the Protein Data Bank with accession code PDB: 6DFJ.
QUANTIFICATION AND STATISTICAL ANALYSIS
Information on the statistical tests used, and the exact values of n and what it represents can be found in the Results and
Figure Legends. Unless otherwise noted, statistical analysis was with Prism software. Luciferase- and flow cytometry-based
neutralization and enhancement assays were performed in triplicate wells, and the antibody concentration (IC50) that neutralized
50% of the virus or RVP inoculum was calculated by nonlinear, dose-response regression analysis. Representatives of at least
two independent experiments are shown throughout, except for ZIKV neutralization (where the mean of two experiments is
shown), and for the measurement of ADE in macaque plasma (where only one assay was performed due to limited amounts of
available plasma). The levels of plasma viremia were measured in triplicates. The Mantel-Cox test was applied to analyze diseasee6 Cell Reports 25, 1385–1394.e1–e7, November 6, 2018
and survival in mice infection experiments and the Mann-Whitney test to determine the significance of the difference in peak viremia
in macaques.
DATA AND SOFTWARE AVAILABILITY
The accession numbers for the structural data reported in this paper are PDB: 6DFI (Z021-ZIKV EDIII complex) and PDB: 6DFJ (Z021-
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